



Please complete ALL information below and fax your request to 1-888-671-5285

# Epclusa® & sofosbuvir/velpatasvir Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

## Medication Information (required)

Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if <b>generic substitution</b> is acceptable		Directions for Use:
<input type="checkbox"/> Check if request is for <b>continuation of therapy</b>		

## Clinical Information (required)

### Select the diagnosis below:

- Chronic Hepatitis C  
 Other diagnosis: \_\_\_\_\_ ICD-10 Code(s): \_\_\_\_\_

### Clinical Information:

Document the patient's hepatitis C virus (HCV) genotype:\* \_\_\_\_\_

Will medical records (e.g., chart notes, laboratory values) be submitted documenting the patient has a diagnosis of chronic hepatitis C virus genotype 1, 2, 3, 4, 5, or 6?\*  Yes  No

*\*Please note: Chart documentation of the above is required to be submitted along with this fax.*

Select if Epclusa (sofosbuvir/velpatasvir) is prescribed by or in consultation with one of the following:

- Gastroenterologist       HIV specialist  
 Hepatologist               Infectious disease specialist

Will the patient be receiving Epclusa (sofosbuvir/velpatasvir) in combination with another HCV direct acting anti-viral agent [e.g., Sovaldi (sofosbuvir), Olysio (simeprevir)]?  Yes  No

Does the patient have decompensated liver disease?  Yes  No

Will Epclusa (sofosbuvir/velpatasvir) be used in combination with ribavirin?  Yes  No

Is the patient ribavirin intolerant or ineligible?  Yes  No

Will Epclusa (sofosbuvir/velpatasvir) be used alone (monotherapy)?  Yes  No

Does the patient have prior failure (defined as viral relapse, breakthrough while on therapy, or non-responder therapy) to Sovaldi or NS5A-based treatment?  Yes  No

### For generic sofosbuvir/velpatasvir requests, also answer the following:

Select if the patient has had trial and failure, contraindication, or intolerance to the following:

- Brand Harvoni (ledipasvir/sofosbuvir)  
 Mavyret (glecaprevir/pibrentasvir)

Has the patient had trial and failure or intolerance to Brand Epclusa?  Yes  No

If "no" to the above question, is the patient already receiving generic therapy?  Yes  No

Is this request for continuation of prior generic sofosbuvir/velpatasvir?  Yes  No

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of FutureScripts. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: Epclusa\_sofosbuvir-velpatasvir\_FSP\_2019Jul-W



**Epclusa® & sofosbuvir/velpatasvir Prior Authorization Request Form (Page 2 of 2)**  
DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

**Quantity Limit Requests:**  
What is the quantity requested per DAY? \_\_\_\_\_

**What is the reason for exceeding the plan limitations?**

- Titration or loading dose purposes
- Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
- Requested strength/dose is not commercially available
- Other: \_\_\_\_\_

**Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?**

---

---

Please note: This request may be denied unless all required information is received.